Biomarkers · Inflammation
Immunoglobulin A (IgA)
Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
IgA and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
Published risk of death1.08×per 1 SD increase in IgA (95% CI 1.02–1.13) · Meta-analysis of Augsburg MONICA/KORA, MONICA Glasgow, Speedwell and one other published study with baseline Ig levels (n=8218)
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ Solid cancer (untreated) · serum IgA in patients with histologically confirmed solid cancer vs controls, before anticancer treatment | SMD +1.5 (95% CI 0.96 to 2.04) | solid cancer vs controls · 1351 cases and 560 controls, 11 case-control studies | meta analysis · PMID 31915145 |
Sources
- Risk curve: Lowe 2024 (PMID 36828622): all-cause HR 1.08 (1.02-1.13) per 1 SD increase in IgA. Scaled to published population values.
- Lowe et al. Plasma viscosity, immunoglobulins and risk of cardiovascular disease and mortality: new data and meta-analyses. Journal of clinical pathology. 2024;77:394-401.
Map Immunoglobulin A (IgA) against another biomarker.
Related markers: Alpha-1-Antichymotrypsin (AACT) · Alpha-1-Antitrypsin (AAT) · Antinuclear Antibodies (ANA) · CD4:CD8 T-Cell Ratio · CD8+ T-Cell Count · Erythrocyte Sedimentation Rate (ESR) · Fibrinogen · Growth Differentiation Factor-15 (GDF-15)